Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Renal Insufficiency, Chronic | 18 | 2024 | 170 | 8.290 |
Why?
|
| Renal Dialysis | 10 | 2022 | 171 | 3.980 |
Why?
|
| Kidney Failure, Chronic | 9 | 2022 | 199 | 3.860 |
Why?
|
| Purinergic P2Y Receptor Antagonists | 5 | 2022 | 29 | 3.280 |
Why?
|
| Thrombosis | 5 | 2024 | 249 | 2.420 |
Why?
|
| Platelet Aggregation Inhibitors | 6 | 2023 | 174 | 2.130 |
Why?
|
| Blood Platelets | 3 | 2024 | 252 | 2.060 |
Why?
|
| Cardiovascular Diseases | 4 | 2022 | 449 | 1.540 |
Why?
|
| Depressive Disorder, Major | 3 | 2019 | 150 | 1.220 |
Why?
|
| Sertraline | 3 | 2019 | 46 | 1.210 |
Why?
|
| Warfarin | 2 | 2019 | 83 | 1.180 |
Why?
|
| Inflammation | 3 | 2024 | 608 | 0.990 |
Why?
|
| Receptors, Purinergic | 1 | 2024 | 14 | 0.920 |
Why?
|
| Platelet Aggregation | 3 | 2023 | 71 | 0.880 |
Why?
|
| Troponin T | 4 | 2022 | 13 | 0.850 |
Why?
|
| Ticlopidine | 3 | 2023 | 55 | 0.830 |
Why?
|
| Humans | 29 | 2024 | 50201 | 0.680 |
Why?
|
| Drug Substitution | 1 | 2019 | 9 | 0.660 |
Why?
|
| Sepsis | 1 | 2021 | 226 | 0.630 |
Why?
|
| Hemorrhage | 1 | 2019 | 196 | 0.580 |
Why?
|
| Hypocalcemia | 1 | 2017 | 12 | 0.580 |
Why?
|
| Hyperparathyroidism | 1 | 2017 | 31 | 0.570 |
Why?
|
| Parathyroidectomy | 1 | 2017 | 46 | 0.560 |
Why?
|
| Atrial Fibrillation | 1 | 2019 | 182 | 0.550 |
Why?
|
| Bone Diseases, Metabolic | 1 | 2017 | 73 | 0.540 |
Why?
|
| Self Report | 2 | 2019 | 202 | 0.520 |
Why?
|
| Calcium | 2 | 2017 | 400 | 0.520 |
Why?
|
| Anticoagulants | 1 | 2018 | 253 | 0.500 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2016 | 322 | 0.490 |
Why?
|
| Acute Coronary Syndrome | 1 | 2016 | 78 | 0.480 |
Why?
|
| Drinking | 1 | 2014 | 38 | 0.480 |
Why?
|
| Sodium Chloride, Dietary | 1 | 2014 | 31 | 0.470 |
Why?
|
| Aspirin | 1 | 2015 | 111 | 0.470 |
Why?
|
| Primary Prevention | 1 | 2014 | 44 | 0.470 |
Why?
|
| Dialysis Solutions | 1 | 2014 | 3 | 0.460 |
Why?
|
| Hyperphosphatemia | 1 | 2014 | 3 | 0.460 |
Why?
|
| Middle Aged | 11 | 2023 | 12356 | 0.460 |
Why?
|
| Phosphate-Binding Proteins | 1 | 2014 | 6 | 0.460 |
Why?
|
| Potassium, Dietary | 1 | 2014 | 2 | 0.460 |
Why?
|
| Natriuretic Peptide, Brain | 3 | 2022 | 29 | 0.460 |
Why?
|
| Sodium, Dietary | 1 | 2014 | 23 | 0.440 |
Why?
|
| Platelet Count | 2 | 2024 | 74 | 0.440 |
Why?
|
| Administration, Oral | 3 | 2019 | 432 | 0.440 |
Why?
|
| Treatment Outcome | 7 | 2023 | 5203 | 0.440 |
Why?
|
| Acid-Base Equilibrium | 1 | 2012 | 9 | 0.410 |
Why?
|
| Adiposity | 1 | 2014 | 132 | 0.410 |
Why?
|
| Male | 14 | 2023 | 25572 | 0.400 |
Why?
|
| Hyperkalemia | 1 | 2012 | 11 | 0.400 |
Why?
|
| Potassium | 1 | 2012 | 56 | 0.390 |
Why?
|
| Percutaneous Coronary Intervention | 1 | 2016 | 299 | 0.390 |
Why?
|
| Female | 14 | 2023 | 26829 | 0.390 |
Why?
|
| Veterans | 1 | 2018 | 570 | 0.380 |
Why?
|
| Evidence-Based Medicine | 1 | 2012 | 247 | 0.370 |
Why?
|
| Risk Factors | 6 | 2019 | 3644 | 0.340 |
Why?
|
| Depressive Disorder | 1 | 2012 | 336 | 0.340 |
Why?
|
| Glomerular Filtration Rate | 4 | 2019 | 111 | 0.340 |
Why?
|
| Kidney Diseases | 1 | 2012 | 212 | 0.330 |
Why?
|
| Adenosine | 2 | 2023 | 70 | 0.330 |
Why?
|
| Aged | 7 | 2022 | 9505 | 0.320 |
Why?
|
| Kidney | 2 | 2017 | 677 | 0.320 |
Why?
|
| Pyridones | 2 | 2019 | 35 | 0.310 |
Why?
|
| Prognosis | 5 | 2019 | 1963 | 0.300 |
Why?
|
| Pyrazoles | 2 | 2019 | 111 | 0.290 |
Why?
|
| Cause of Death | 3 | 2019 | 146 | 0.280 |
Why?
|
| Prospective Studies | 4 | 2019 | 2396 | 0.270 |
Why?
|
| Risk Assessment | 3 | 2019 | 1255 | 0.270 |
Why?
|
| Obesity | 1 | 2014 | 1112 | 0.250 |
Why?
|
| Prevalence | 2 | 2019 | 960 | 0.250 |
Why?
|
| Peptide Fragments | 2 | 2017 | 207 | 0.240 |
Why?
|
| Albuminuria | 2 | 2022 | 45 | 0.240 |
Why?
|
| Disease Progression | 3 | 2019 | 821 | 0.240 |
Why?
|
| Time Factors | 3 | 2019 | 2909 | 0.240 |
Why?
|
| Purinergic Antagonists | 1 | 2024 | 7 | 0.230 |
Why?
|
| Antidepressive Agents | 2 | 2017 | 176 | 0.230 |
Why?
|
| Hemostasis | 1 | 2024 | 56 | 0.220 |
Why?
|
| Adult | 7 | 2019 | 13486 | 0.210 |
Why?
|
| Retrospective Studies | 3 | 2022 | 6190 | 0.200 |
Why?
|
| Coronary Artery Disease | 2 | 2017 | 273 | 0.200 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2022 | 79 | 0.190 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2015 | 1356 | 0.180 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2022 | 388 | 0.180 |
Why?
|
| Double-Blind Method | 2 | 2019 | 682 | 0.180 |
Why?
|
| Case-Control Studies | 1 | 2023 | 1145 | 0.170 |
Why?
|
| Hypertrophy, Left Ventricular | 2 | 2017 | 39 | 0.170 |
Why?
|
| E-Selectin | 1 | 2019 | 14 | 0.170 |
Why?
|
| Intention to Treat Analysis | 1 | 2019 | 27 | 0.170 |
Why?
|
| Arachidonic Acid | 1 | 2019 | 34 | 0.170 |
Why?
|
| Placebos | 1 | 2019 | 85 | 0.170 |
Why?
|
| P-Selectin | 1 | 2019 | 32 | 0.170 |
Why?
|
| Cytokines | 1 | 2022 | 607 | 0.170 |
Why?
|
| Peritoneal Dialysis | 1 | 2019 | 32 | 0.170 |
Why?
|
| Platelet Activation | 1 | 2019 | 47 | 0.160 |
Why?
|
| Drug Utilization | 1 | 2019 | 75 | 0.160 |
Why?
|
| Drug Prescriptions | 1 | 2019 | 95 | 0.160 |
Why?
|
| Proportional Hazards Models | 2 | 2017 | 408 | 0.160 |
Why?
|
| Follow-Up Studies | 2 | 2015 | 2188 | 0.160 |
Why?
|
| Fatigue | 1 | 2019 | 118 | 0.160 |
Why?
|
| Needs Assessment | 1 | 2019 | 133 | 0.160 |
Why?
|
| Antidotes | 1 | 2018 | 25 | 0.150 |
Why?
|
| International Normalized Ratio | 1 | 2018 | 28 | 0.150 |
Why?
|
| Antithrombins | 1 | 2018 | 19 | 0.150 |
Why?
|
| Thiazoles | 1 | 2018 | 53 | 0.150 |
Why?
|
| Patient Selection | 1 | 2019 | 254 | 0.150 |
Why?
|
| United States | 2 | 2019 | 4898 | 0.150 |
Why?
|
| Hyperparathyroidism, Secondary | 1 | 2017 | 4 | 0.150 |
Why?
|
| Calcitriol | 1 | 2017 | 39 | 0.140 |
Why?
|
| Vascular Calcification | 1 | 2017 | 17 | 0.140 |
Why?
|
| Signal Transduction | 1 | 2024 | 1612 | 0.140 |
Why?
|
| Pyridines | 1 | 2018 | 132 | 0.140 |
Why?
|
| Young Adult | 2 | 2019 | 4052 | 0.140 |
Why?
|
| Survival Rate | 1 | 2019 | 906 | 0.140 |
Why?
|
| Syndrome | 1 | 2017 | 239 | 0.140 |
Why?
|
| Bone Density Conservation Agents | 1 | 2017 | 74 | 0.140 |
Why?
|
| Diphosphonates | 1 | 2017 | 90 | 0.130 |
Why?
|
| Registries | 1 | 2019 | 527 | 0.130 |
Why?
|
| Texas | 2 | 2017 | 143 | 0.130 |
Why?
|
| Platelet Function Tests | 1 | 2015 | 17 | 0.130 |
Why?
|
| ROC Curve | 1 | 2016 | 236 | 0.130 |
Why?
|
| Diet, Sodium-Restricted | 1 | 2014 | 5 | 0.120 |
Why?
|
| Drug Therapy, Combination | 1 | 2015 | 382 | 0.120 |
Why?
|
| Calcinosis | 1 | 2014 | 52 | 0.120 |
Why?
|
| Stroke | 1 | 2019 | 479 | 0.110 |
Why?
|
| Nutrition Surveys | 1 | 2014 | 103 | 0.110 |
Why?
|
| Linear Models | 1 | 2014 | 279 | 0.110 |
Why?
|
| Triglycerides | 1 | 2014 | 153 | 0.110 |
Why?
|
| Feeding Behavior | 1 | 2014 | 177 | 0.110 |
Why?
|
| Aged, 80 and over | 2 | 2019 | 3158 | 0.100 |
Why?
|
| Alcohol Drinking | 1 | 2014 | 221 | 0.100 |
Why?
|
| Hospitalization | 1 | 2016 | 665 | 0.100 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2014 | 553 | 0.100 |
Why?
|
| Sex Factors | 1 | 2014 | 700 | 0.100 |
Why?
|
| Patient Education as Topic | 1 | 2014 | 314 | 0.090 |
Why?
|
| Blood Pressure | 1 | 2014 | 527 | 0.090 |
Why?
|
| Blood Glucose | 1 | 2014 | 434 | 0.090 |
Why?
|
| Body Mass Index | 1 | 2014 | 658 | 0.090 |
Why?
|
| Animals | 1 | 2024 | 13141 | 0.080 |
Why?
|
| Heart Diseases | 1 | 2011 | 211 | 0.080 |
Why?
|
| Adolescent | 1 | 2019 | 6459 | 0.070 |
Why?
|
| Longitudinal Studies | 2 | 2019 | 700 | 0.060 |
Why?
|
| Survival Analysis | 1 | 2019 | 670 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2017 | 463 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2019 | 959 | 0.030 |
Why?
|
| Coronary Angiography | 1 | 2017 | 353 | 0.030 |
Why?
|
| Carotid Intima-Media Thickness | 1 | 2014 | 9 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2017 | 921 | 0.030 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2014 | 100 | 0.030 |
Why?
|
| Depression | 1 | 2017 | 571 | 0.030 |
Why?
|
| Quality of Life | 1 | 2017 | 843 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2017 | 1529 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2014 | 1160 | 0.020 |
Why?
|